The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications
Open accessAbstract
CONTEXT: Modafinil, a wake-promoting drug used to treat narcolepsy, is increasingly being used as a cognitive enhancer. Although initially launched as distinct from stimulants that increase extracellular dopamine by targeting dopamine transporters, recent preclinical studies suggest otherwise. OBJECTIVE: To measure the acute effects of modafinil at doses used therapeutically (200 mg and 400 mg given orally) on extracellular dopamine and on dopamine transporters in the male human brain. DESIGN, SETTING, AND PARTICIPANTS: Positron emission tomography with [(11)C]raclopride (D(2)/D(3) radioligand sensitive to changes in endogenous dopamine) and [(11)C]cocaine (dopamine transporter radioligand) was used to measure the effects of modafinil on extracellular dopamine and on dopamine transporters in 10 healthy male participants. The study took place over an 8-month period (2007-2008) at Brookhaven National Laboratory. MAIN OUTCOME MEASURES: Primary outcomes were changes in dopamine D(2)/D(3) receptor and dopamine transporter availability (measured by changes in binding potential) after modafinil when compared with after placebo. RESULTS: Modafinil decreased mean (SD) [(11)C]raclopride binding potential in caudate (6.1% [6.5%]; 95% confidence interval [CI], 1.5% to 10.8%; P = .02), putamen (6.7% [4.9%]; 95% CI, 3.2% to 10.3%; P = .002), and nucleus accumbens (19.4% [20%]; 95% CI, 5% to 35%; P = .02), reflecting increases in extracellular dopamine. Modafinil also decreased [(11)C]cocaine binding potential in caudate (53.8% [13.8%]; 95% CI, 43.9% to 63.6%; P < .001), putamen (47.2% [11.4%]; 95% CI, 39.1% to 55.4%; P < .001), and nucleus accumbens (39.3% [10%]; 95% CI, 30% to 49%; P = .001), reflecting occupancy of dopamine transporters. CONCLUSIONS: In this pilot study, modafinil blocked dopamine transporters and increased dopamine in the human brain (including the nucleus accumbens). Because drugs that increase dopamine in the nucleus accumbens have the potential for abuse, and considering the increasing use of modafinil, these results highlight the need for heightened awareness for potential abuse of and dependence on modafinil in vulnerable populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arky, R. A. (1994) · Cited by 2,632
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationCrone, C. (1963) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1963.tb02652.x · Cited by 1,153
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 1×
“Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (ie, schizophrenia, attention-deficit/ hyperactivity disorder [ADHD]).(1) Moreover, modafinil is increasingly being diverted for nonmedical use by healthy individuals with the expectation that…”
BackgroundHypothalamic Arousal Regions Are Activated during Modafinil-Induced Wakefulness
Scammell, T. E., Estabrooke, I. V., McCarthy, M. T., Chemelli, R. M., Yanagisawa, M., Miller, M. S., & Saper, C. B. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-22-08620.2000 · Cited by 485
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Jayne, M., Franceschi, D., Wong, C., Gatley, S. J., Gifford, A. N., Ding, Y., et al. (2002) · Synapse · doi:10.1002/syn.10075 · Cited by 452
Self-citationThe Physicians' Desk Reference: Problems and Possible Improvements
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 428
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379
Self-citationMadras, B. K., Xie, Z., Lin, Z., Jassen, A., Panas, H., Lynch, L., Johnson, R., Livni, E., Spencer, T. J., Bonab, A. A., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106583 · Cited by 326
Volkow, N., & Li, T.-K. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1429 · Cited by 324
Self-citationVolkow, N. D., Wang, G., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., Ding, Y., Gatley, S. J., Gifford, A., Zhu, W., et al. (2002) · Synapse · doi:10.1002/syn.10038 · Cited by 321
Self-citationLin, J.-S., Hou, Y., & Jouvet, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14128 · Cited by 300
Jasinski, D. R., & Kovačević-Ristanović, R. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200005000-00004 · Cited by 292
Mapping cocaine binding sites in human and baboon brain in vivo
Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Logan, J., Bendriem, B., Gatley, S. J., et al. (1989) · Synapse · doi:10.1002/syn.890040412 · Cited by 290
Self-citationDopaminergic D1and D2Receptors Are Essential for the Arousal Effect of Modafinil
Qu, W.-M., Huang, Z.-L., Xu, X.-H., Matsumoto, N., & Urade, Y. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1819-08.2008 · Cited by 230
Modafinil Shifts Human Locus Coeruleus to Low-Tonic, High-Phasic Activity During Functional MRI
Minzenberg, M. J., Watrous, A. J., Yoon, J. H., Ursu, S., & Carter, C. S. (2008) · Science · doi:10.1126/science.1164908 · Cited by 188
Smoked Cocaine Self-Administration is Decreased by Modafinil
Hart, C. L., Haney, M., Vosburg, S. K., Rubin, E., & Foltin, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301472 · Cited by 174
Logan, J., Volkow, N. D., Fowler, J. S., Wang, G.-J., Dewey, S. L., MacGregor, R., Schlyer, D., Gatley, S. J., Pappas, N., King, P., et al. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.132 · Cited by 167
Self-citationde Saint-Hilaire, Z., Orosco, M., Rouch, C., Blanc, G., & Nicolaidis, S. (2001) · NeuroReport · doi:10.1097/00001756-200111160-00032 · Cited by 156
Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil
Gold, L. H., & Balster, R. L. (1996) · Psychopharmacology · doi:10.1007/bf02247379 · Cited by 153
Ferraro, L., Antonelli, T., O'Connor, W. T., Tanganelli, S., Rambert, F. A., & Fuxé, K. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00353-3 · Cited by 140
Modafinil: Preclinical, Clinical, and Post-Marketing Surveillance—A Review of Abuse Liability Issues
Myrick, H., Malcolm, R. J., Taylor, B. R., & LaRowe, S. D. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490453743 · Cited by 138
Murillo‐Rodríguez, E., Haro, R., Palomero‐Rivero, M., Millán‐Aldaco, D., & Drucker-Colı́n, R. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.10.016 · Cited by 94
Ehrin, E., Gawell, L., Högberg, T., de Paulis, T., & Ström, P. (1987) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580240808 · Cited by 86
Stoops, W. W., Lile, J. A., Fillmore, M. T., Glaser, P. E. A., & Rush, C. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0044-1 · Cited by 85
Wang, G., Volkow, N. D., HITZEMANN, R. J., Wong, C., ANGRIST, B. M., Burr, G., Pascani, K., Pappas, N. R., Lu, A., Cooper, T. B., et al. (2009) · European Addiction Research · doi:10.1159/000259147 · Cited by 70
Self-citationBiederman, J., Swanson, J. M., Wigal, S. B., Boellner, S. W., Earl, C. Q., López, F. A., & Modafinil ADHD Study Group (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0506 · Cited by 58
Plasma input function determination for PET using a commercial laboratory robot
Alexoff, D. L., Shea, C. E., Fowler, J. S., King, P. T., Gatley, S. J., Schlyer, D. J., & Wolf, A. P. (1995) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(95)00042-v · Cited by 56
Self-citationGjedde, A., Wong, D. F., Rosa-Neto, P., & Cumming, P. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(05)63001-2 · Cited by 50
Joo, E. Y., Tae, W., JUNG, K., & Hong, S. B. (2008) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2008.00624.x · Cited by 42
The Science of Stimulant Abuse
Greenhill, L. L. (2006) · Pediatric Annals · doi:10.3928/0090-4481-20060801-07 · Cited by 30
Euphorigenic and Abusive Properties of Modafinil
KRUSZEWSKI, S. P. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.549 · Cited by 22
Schizophrenia Symptoms Remain Stable During Decreases From 2 Antipsychotics to Aripiprazole
Salzman, C., Rosenberg, J., & Feldman, J. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624a · Cited by 7
Modafinil: Mischaracterization
Kruszewski, S. P., & Klotz, S. G. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624b · Cited by 5
The Science of Stimulant Abuse
Greenhill, L. L. (2005) · Psychiatric Annals · doi:10.3928/00485713-20050301-04 · Cited by 4
Cited by
The dopamine theory of addiction: 40 years of highs and lows
Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3939 · Cited by 649
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.04.002 · Cited by 576
The comorbidity of insomnia, chronic pain, and depression: Dopamine as a putative mechanism
Finan, P. H., & Smith, M. T. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.03.003 · Cited by 363
Brain default-mode network dysfunction in addiction
Zhang, R., & Volkow, N. D. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.036 · Cited by 363
Self-citation
Metadata
- Authors
- Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., Hubbard, B., Carter, P., Warner, D., King, P., Shea, C., Xu, Y., Muench, L., & Apelskog-Torres, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-18
- Volume
- 301
- Issue
- 11
- Pages
- 1148
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2055500305
- Cited by
- 529
- References
- 38
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.